PAIOF (Paion AG) Research & Development: $5.42 Mil (TTM As of Jun. 2023)


PAIOF Paion AG PAIOF
10 GF Score
Price $0.01
View Full Analysis

What is Paion AG Research & Development?

Paion AG PAIOF +9,900.00% 10 Research & Development is $5.42 Mil as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

Research & Development is the aggregate amount of research and development expenses during the year. Paion AG's Research & Development for the six months ended in Jun. 2023 was $1.79 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $5.42 Mil.

Paion AG  (OTCPK:PAIOF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Paion AG Research & Development Related Terms

Paion AG Research & Development Historical Data

* Premium members only.

The historical data trend for Paion AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Research & Development Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.84 14.55 12.52 5.93 6.87

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 2.64 3.23 3.64 1.79
PAIOF
10GF Score
Paion AG PAIOF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.42 Mil mean?
Paion AG (PAIOF) has a Research & Development of $5.42 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Paion AG and its competitors.
Is Paion AG's Research & Development too high?
Paion AG's current Research & Development is $5.42 Mil. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Research & Development compare to ZTS and NBIX?
Paion AG's Research & Development of $5.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Paion AG and its competitors. Paion AG's current Research & Development is $5.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Research & Development of $5.42 Mil. The current Research & Development is $5.42 Mil. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Paion AG (PAIOF), the current Research & Development is $5.42 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price